0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Editorial  | 
Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet?
S. Percy Ivy, MD; Jan H. Beumer, PharmD, PhD
JAMA Oncology
Invited Commentary  | 
Multiple Myeloma—Better Drugs Ask for More Stringent Evaluations
Pieter Sonneveld, MD, PhD
JAMA Oncology
Original Investigation  | 
Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index
Elisa V. Bandera, MD, PhD; Valerie S. Lee, MHS; Lorna Rodriguez-Rodriguez, MD, PhD; et al.
JAMA Oncology
Original Investigation  | 
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde, MD; Mark Roschewski, MD; Adriana Zingone, MD, PhD; et al.